Table 2.
Proportion of participants with seroconversion (immunogenicity analysis population).
| Anti-S |
Anti-RBD |
nAbs |
|||||
|---|---|---|---|---|---|---|---|
| Timepoint | Statistic | SII-ChAdOx1 nCoV-19 (N = 297) |
AZD1222 (N = 98) |
SII-ChAdOx1 nCoV-19 (N = 297) |
AZD1222 (N = 98) |
SII-ChAdOx1 nCoV-19 (N = 297) |
AZD1222 (N = 98) |
| Visit 4 – Day 57 (+14) | N evaluated | 293 | 95 | 293 | 95 | 291 | 95 |
| Seroconversion, n (%)* | 287 (98.0) | 94 (98.9) | 284 (96.9) | 93 (97.9) | 249 (85.6) | 80 (84.2) | |
| 95% CI | 95.6–99.2 | 94.3–100.0 | 94.2–98.6 | 92.6–99.7 | 81.0–89.4 | 75.3–90.9 | |
| Visit 6 – Day 180 (+28) | N evaluated | 258 | 88 | 258 | 88 | 83 | 29 |
| Seroconversion, n (%)* | 243 (94.2) | 85 (96.6) | 236 (91.5) | 82 (93.2) | 47 (56.6) | 15 (51.7) | |
| 95% CI | 90.6–96.7 | 90.4–99.3 | 87.4–94.6 | 85.7–97.5 | 45.3–67.5 | 32.5–70.6 | |
*Seroconversion is defined as 4-fold rise in titer from baseline. Anti-RBD, anti-receptor binding domain; anti-S, anti-spike; CI, confidence interval; nAb, neutralizing antibody.